OXPROTECT GMBH

Their core work

OxProtect is a German SME based in Münster that provides specialized expertise in biomedical product characterization, regulatory science for nanomedicine, and reproductive medicine research. Their work spans the assessment and regulatory evaluation of nano-biomaterial-based medical devices, as well as translational research on conditions like endometriosis. They primarily contribute niche technical or advisory services to larger European research consortia rather than leading projects themselves.

What they specialise in

How they've shifted over time

OxProtect's early H2020 involvement (2015–2019) centered on nanomedicine infrastructure and regulatory science for nano-biomaterial medical devices, contributing as a third party to characterization and risk assessment efforts. From 2021 onward, they shifted toward reproductive medicine and endometriosis research, marking a move from regulatory/characterization support into translational biomedical research. This transition suggests the company may be broadening from a pure regulatory advisory role into active participation in disease-focused research.

OxProtect appears to be pivoting from nanomedicine regulation toward translational reproductive medicine, suggesting potential future collaborations in gynecological research and women's health.

How they like to work

OxProtect operates almost exclusively as a supporting contributor — two of three projects are third-party roles and none as coordinator. Despite this peripheral involvement, they have touched consortia spanning 26 partners across 16 countries, indicating they plug into large, well-connected networks without driving them. This profile suggests a specialist that provides targeted expertise on demand rather than shaping project direction.

Through just three projects, OxProtect has been linked to 26 unique consortium partners across 16 countries, reflecting the breadth of the large consortia they contribute to rather than a deliberately built network of their own.

What sets them apart

OxProtect occupies an unusual niche at the intersection of nanomedicine regulatory assessment and reproductive medicine — two fields rarely combined in a single SME. Their regulatory science background from EUNCL and REFINE could be valuable for any consortium developing medical devices or nanomedicine products that need regulatory pathway expertise. However, their very small funding footprint and third-party roles suggest they are a micro-specialist best suited for targeted contributions rather than major partnership commitments.

Highlights from their portfolio

• REFINE
  Addressed the regulatory framework for nano-biomaterial medical products and devices, covering risk assessment, decision support, and medicinal innovation — a strategically important topic for the European nanomedicine sector.
• TRENDO
  Represents a clear pivot into translational endometriosis research involving microRNA and stem cells, and is OxProtect's only project as a direct participant with EC funding.